Endocrine complications of human immunodeficiency virus infection: Hypogonadism, bone disease and tenofovir-related toxicity

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 25, Issue 3, 2011, Pages 501-515

  Cotter, Aoife G ^a   Powderly, William G ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

bone disease; endocrine complications; hypogonadism; tenofovir; vitamin D

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BONE DEMINERALIZATION; BONE DENSITY; BONE DISEASE; BONE NECROSIS; COMORBIDITY; DISEASE ASSOCIATION; ENDOCRINE DISEASE; FRAGILITY FRACTURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGONADISM; KIDNEY DYSFUNCTION; OSTEOMALACIA; OSTEOPOROSIS; SIDE EFFECT; SURVIVAL; WASTING SYNDROME;

EID: 79958296482     PISSN: 1521690X     EISSN: 15321908     Source Type: Journal    
DOI: 10.1016/j.beem.2010.11.003     Document Type: Review

References (121)

1. F.J. Palella Jr., K.M. Delaney, A.C. Moorman HIV Outpatient Study Investigators Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection The New England Journal of Medicine 338 13 1998 853 860 (Pubitemid 28135961)
2. J. Neuhaus, B. Angus, and J.D. Kowalska Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV AIDS 24 5 2010 697 706
3. A.S. Dobs, M.A. Dempsey, and P.W. Ladenson Endocrine disorders in men infected with human immunodeficiency virus American Journal of Medicine 84 3 Pt 2 1988 611 616
4. O. Moreno-Perez, C. Escoin, and C. Serna-Candel The determination of total testosterone and free testosterone (RIA) are not applicable to the evaluation of gonadal function in HIV-infected males Journal of Sexual Medicine 2010
5. N.F. Crum-Cianflone, M. Bavaro, and B. Hale Erectile dysfunction and hypogonadism among men with HIV AIDS Patient Care and STDS 21 1 2007 9 19 (Pubitemid 46214159)
6. P. Rietschel, C. Corcoran, and T. Stanley Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy Clinical Infectious Diseases 31 5 2000 1240 1244 (Pubitemid 32295456)
7. R.S. Klein, Y. Lo, and N. Santoro Androgen levels in older men who have or who are at risk of acquiring HIV infection Clinical Infectious Diseases 41 12 2005 1794 1803 (Pubitemid 41759867)
8. A.B. Chabon, R.J. Stenger, and H. Grabstald Histopathology of testis in acquired immune deficiency syndrome Urology 29 6 1987 658 663 (Pubitemid 17078215)
9. M.E. De Paepe, J.C. Vuletin, and M.H. Lee Testicular atrophy in homosexual AIDS patients: an immune-mediated phenomenon? Human Pathology 20 6 1989 572 578 (Pubitemid 19164367)
10. M.M. Shevchuk, G.J. Nuovo, and G. Khalife HIV in testis: quantitative histology and HIV localization in germ cells Journal of Reproductive Immunology 41 1-2 1998 69 79 (Pubitemid 29017866)
11. M.M. Shevchuk, J.B. Pigato, and G. Khalife Changing testicular histology in AIDS: its implication for sexual transmission of HIV Urology 53 1 1999 203 208 (Pubitemid 29016639)
12. D.E. Sellmeyer, and C. Grunfeld Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome Endocrine Reviews 17 5 1996 518 532 (Pubitemid 26346641)
13. J. Cofrancesco Jr., J.J. Whalen 3rd, and A.S. Dobs Testosterone replacement treatment options for HIV-infected men Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 16 4 1997 254 265
14. L. Membreno, I. Irony, and W. Dere Adrenocortical function in acquired immunodeficiency syndrome Journal of Clinical Endocrinology and Metabolism 65 3 1987 482 487 (Pubitemid 17131436)
15. S. Grinspoon, C. Corcoran, and T. Stanley Mechanisms of androgen deficiency in human immunodeficiency virus-infected women with the wasting syndrome Journal of Clinical Endocrinology and Metabolism 86 9 2001 4120 4126 (Pubitemid 32848523)
16. S.A. Rivkees, and J.D. Crawford The relationship of gonadal activity and chemotherapy-induced gonadal damage JAMA 259 14 1988 2123 2125 (Pubitemid 18088500)
17. N. Sakane, T. Yoshida, and K. Yoshioka Reversible hypopituitarism after interferonalfa therapy Lancet 345 8960 1995 1305
18. G. Wagner, J.G. Rabkin, and R. Rabkin Illness stage, concurrent medications, and other correlates of low testosterone in men with HIV illness Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 8 2 1995 204 207
19. O.B. Cooper, T.T. Brown, and A.S. Dobs Opiate drug use: a potential contributor to the endocrine and metabolic complications in human immunodeficiency virus disease Clinical Infectious Diseases 37 Suppl. 2 2003 S132 S136
20. J.E. Morley, E. Charlton, and P. Patrick Validation of a screening questionnaire for androgen deficiency in aging males Metabolism 49 9 2000 1239 1242
21. M.E. Martin, C. Benassayag, and C. Amiel Alterations in the concentrations and binding properties of sex steroid binding protein and corticosteroid-binding globulin in HIV+ patients Journal of Endocrinological Investigation 15 8 1992 597 603
22. J.D. Scott, P.R. Wolfe, and P. Anderson Prospective study of topical testosterone gel (AndroGel) versus intramuscular testosterone in testosterone-deficient HIV-infected men HIV Clinical Trials 8 6 2007 412 420 (Pubitemid 350305215)
23. A.S. Dobs, J. Cofrancesco, and W.E. Nolten The use of a transscrotal testosterone delivery system in the treatment of patients with weight loss related to human immunodeficiency virus infection American Journal of Medicine 107 2 1999 126 132 (Pubitemid 29383965)
24. S. Bhasin, T.W. Storer, and N. Asbel-Sethi Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels Journal of Clinical Endocrinology and Metabolism 83 9 1998 3155 3162 (Pubitemid 28500950)
25. S. Grinspoon, C. Corcoran, and E. Anderson Sustained anabolic effects of long-term androgen administration in men with AIDS wasting Clinical Infectious Diseases 28 3 1999 634 636 (Pubitemid 29242546)
26. S. Bhasin, T.W. Storer, and M. Javanbakht Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels JAMA 283 6 2000 763 770 (Pubitemid 30084616)
27. S. Grinspoon, C. Corcoran, and T. Stanley Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men Journal of Clinical Endocrinology and Metabolism 85 1 2000 60 65 (Pubitemid 32268790)
28. J.G. Rabkin, G.J. Wagner, and R. Rabkin A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms Archives of General Psychiatry 57 2 2000 141 147 (Pubitemid 30075264)
29. S. Grinspoon, C. Corcoran, and K. Miller Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting Journal of Clinical Endocrinology and Metabolism 82 5 1997 1332 1337 (Pubitemid 27200397)
30. E. Mylonakis, P. Koutkia, and S. Grinspoon Diagnosis and treatment of androgen deficiency in human immunodeficiency virus-infected men and women Clinical Infectious Diseases 33 6 2001 857 864 (Pubitemid 32831843)
31. S.E. Dolan Looby, M. Collins, and H. Lee Effects of long-term testosterone administration in HIV-infected women: a randomized, placebo-controlled trial AIDS 23 8 2009 951 959
32. A.N. Scribner, P.V. Troia-Cancio, and B.A. Cox Osteonecrosis in HIV: a case-control study Journal of Acquired Immune Deficiency Syndromes 25 1 2000 19 25
33. X. Chevalier, B. Larget-Piet, and P. Hernigou Avascular necrosis of the femoral head in HIV-infected patients The Journal of Bone and Joint Surgery. British Volume 75 1 1993 160 (Pubitemid 23052442)
34. J. Llauger, J. Palmer, and N. Roson Osteonecrosis of the knee in an HIV-infected patient AJR American Journal of Roentgenology 171 4 1998 987 988 (Pubitemid 28449958)
35. R.H. Mullan, and P.F. Ryan Multiple site osteonecrosis in HIV infection Rheumatology (Oxford) 41 10 2002 1200 1202 (Pubitemid 35203556)
36. F. Gutierrez, S. Padilla, and M. Masia Osteonecrosis in patients infected with HIV: clinical epidemiology and natural history in a large case series from Spain Journal of Acquired Immune Deficiency Syndromes 42 3 2006 286 292 (Pubitemid 44050005)
37. B.P. Goorney, H. Lacey, and S. Thurairajasingam Avascular necrosis of the hip in a man with HIV infection Genitourinary Medicine 66 6 1990 451 452
38. K.D. Miller, H. Masur, and E.C. Jones High prevalence of osteonecrosis of the femoral head in HIV-infected adults Annals of Internal Medicine 137 1 2002 17 25
39. C.G. Morse, J.M. Mican, and E.C. Jones The incidence and natural history of osteonecrosis in HIV-infected adults Clinical Infectious Diseases 44 5 2007 739 748
40. F. Gutierrez, S. Padilla, and E. Ortega Avascular necrosis of the bone in HIV-infected patients: incidence and associated factors AIDS 16 3 2002 481 483 (Pubitemid 34165381)
41. M.A. Matos, R.W. Alencar, and S.S. Matos Avascular necrosis of the femoral head in HIV infected patients The Brazilian Journal of Infectious Diseases 11 1 2007 31 34 (Pubitemid 47024092)
42. R. Reddy, M.N. Daftary, and R. Delapenha Avascular necrosis and protease inhibitors Journal of the National Medical Association 97 11 2005 1543 1546 (Pubitemid 41642533)
43. M.J. Glesby, D.R. Hoover, and C.M. Vaamonde Osteonecrosis in patients infected with human immunodeficiency virus: a case-control study The Journal of Infectious Diseases 184 4 2001 519 523 (Pubitemid 32718519)
44. S. Lawson-Ayayi, F. Bonnet, and E. Bernardin Avascular necrosis in HIV-infected patients: a case-control study from the Aquitaine Cohort, 1997-2002, France Clinical Infectious Diseases 40 8 2005 1188 1193 (Pubitemid 40490247)
45. M. Mary-Krause, E. Billaud, and I. Poizot-Martin Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy AIDS 20 12 2006 1627 1635 (Pubitemid 44162405)
46. G.T. Allison, M.P. Bostrom, and M.J. Glesby Osteonecrosis in HIV disease: epidemiology, etiologies, and clinical management AIDS 17 1 2003 1 9 (Pubitemid 36106293)
47. S. Agarwala, D. Jain, and V.R. Joshi Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study Rheumatology (Oxford) 44 3 2005 352 359 (Pubitemid 40361293)
48. S. Agarwala, S. Shah, and V.R. Joshi The use of alendronate in the treatment of avascular necrosis of the femoral head: follow-up to eight years The Journal of Bone and Joint Surgery. British Volume 91 8 2009 1013 1018
49. T. Nishii, N. Sugano, and H. Miki Does alendronate prevent collapse in osteonecrosis of the femoral head? Clinical Orthopaedics and Related Research 443 2006 273 279 (Pubitemid 44324956)
50. C.M. Klotzbuecher, P.D. Ross, and P.B. Landsman Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis Journal of Bone and Mineral Research 15 4 2000 721 739 (Pubitemid 30174026)
51. P.D. Ross, J.W. Davis, and R.S. Epstein Pre-existing fractures and bone mass predict vertebral fracture incidence in women Annals of Internal Medicine 114 11 1991 919 923
52. J.A. Kanis, O. Johnell, and C. De Laet A meta-analysis of previous fracture and subsequent fracture risk Bone 35 2 2004 375 382 (Pubitemid 38953182)
53. J.R. Center, T.V. Nguyen, and D. Schneider Mortality after all major types of osteoporotic fracture in men and women: an observational study Lancet 353 9156 1999 878 882 (Pubitemid 29126875)
54. J.H. Arnsten, R. Freeman, and A.A. Howard Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection AIDS 21 5 2007 617 623
55. C. Cazanave, M. Dupon, and V. Lavignolle-Aurillac Reduced bone mineral density in HIV-infected patients: prevalence and associated factors AIDS 22 3 2008 395 402
56. S.E. Dolan, J.S. Huang, and K.M. Killilea Reduced bone density in HIV-infected women AIDS 18 3 2004 475 483 (Pubitemid 38365875)
57. M.G. van Vonderen, P. Lips, and M.A. van Agtmael First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir AIDS 23 11 2009 1367 1376
58. C. Duvivier, S. Kolta, and L. Assoumou Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients AIDS 23 7 2009 817 824
59. K. Mondy, K. Yarasheski, and W.G. Powderly Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals Clinical Infectious Diseases 36 4 2003 482 490 (Pubitemid 36241317)
60. C. Amiel, A. Ostertag, and L. Slama BMD is reduced in HIV-infected men irrespective of treatment Journal of Bone and Mineral Research 19 3 2004 402 409 (Pubitemid 38787395)
61. A. Carr, J. Miller, and J.A. Eisman Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy AIDS 15 6 2001 703 709 (Pubitemid 32423217)
62. H. Knobel, A. Guelar, and G. Vallecillo Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS 15 6 2001 807 808 (Pubitemid 32423234)
63. M. Yin, J. Dobkin, and K. Brudney Bone mass and mineral metabolism in HIV+ postmenopausal women Osteoporosis International 16 11 2005 1345 1352 (Pubitemid 41534646)
64. P.W. Mallon HIV and bone mineral density Current Opinion in Infectious Diseases 23 1 2010 1 8
65. S. Serrano, M.L. Marinoso, and J.C. Soriano Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study Bone 16 2 1995 185 191
66. N.I. Paton, D.C. Macallan, and G.E. Griffin Bone mineral density in patients with human immunodeficiency virus infection Calcified Tissue International 61 1 1997 30 32 (Pubitemid 27262397)
67. T.T. Brown, and R.B. Qaqish Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review AIDS 20 17 2006 2165 2174 (Pubitemid 44684707)
68. M.J. Bolland, A.B. Grey, and G.D. Gamble Clinical review #: low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis Journal of Clinical Endocrinology and Metabolism 92 2007 4522 4528 (Pubitemid 350223420)
69. D. Bruera, N. Luna, and D.O. David Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy AIDS 17 13 2003 1917 1923 (Pubitemid 37070277)
70. A. Fausto, M. Bongiovanni, and P. Cicconi Potential predictive factors of osteoporosis in HIV-positive subjects Bone 38 6 2006 893 897 (Pubitemid 44500653)
71. J.E. Gallant, E. DeJesus, and J.R. Arribas Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV The New England Journal of Medicine 354 3 2006 251 260 (Pubitemid 43113030)
72. B. Grund, G. Peng, and C.L. Gibert Continuous antiretroviral therapy decreases bone mineral density AIDS 23 12 2009 1519 1529
73. J.S. Huang, S.J. Wilkie, and M.P. Sullivan Reduced bone density in androgen-deficient women with acquired immune deficiency syndrome wasting Journal of Clinical Endocrinology and Metabolism 86 8 2001 3533 3539 (Pubitemid 32755940)
74. D. Nolan, R. Upton, and E. McKinnon Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir AIDS 15 10 2001 1275 1280 (Pubitemid 32592360)
75. P. Tebas, W.G. Powderly, and S. Claxton Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy AIDS 14 4 2000 F63 F67
76. A.Y. McDermott, A. Shevitz, and T. Knox Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women The American Journal of Clinical Nutrition 74 5 2001 679 686 (Pubitemid 33015155)
77. A.L. Moore, A. Vashisht, and C.A. Sabin Reduced bone mineral density in HIV-positive individuals AIDS 15 13 2001 1731 1733 (Pubitemid 32918130)
78. J. Fernandez-Rivera, R. Garcia, and F. Lozano Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients HIV Clinical Trials 4 5 2003 337 346 (Pubitemid 37304437)
79. S. Jones, D. Restrepo, and A. Kasowitz Risk factors for decreased bone density and effects of HIV on bone in the elderly Osteoporosis International 19 7 2008 913 918
80. A. Hansen, N. Obel, and H. Nielsen Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial HIV Medicine 2010
81. E. Seeman, and P.D. Delmas Bone quality-the material and structural basis of bone strength and fragility The New England Journal of Medicine 354 21 2006 2250 2261
82. P. Ducy, T. Schinke, and G. Karsenty The osteoblast: a sophisticated fibroblast under central surveillance Science 289 5484 2000 1501 1504
83. S.L. Teitelbaum Bone resorption by osteoclasts Science 289 5484 2000 1504 1508
84. E.J. Cotter, H.S. Ip, and W.G. Powderly Mechanism of HIV protein induced modulation of mesenchymal stem cell osteogenic differentiation BMC Musculoskeletal Disorders 9 2008 33
85. R.G. Jain, and J.M. Lenhard Select HIV protease inhibitors alter bone and fat metabolism ex vivo The Journal of Biological Chemistry 277 22 2002 19247 19250 (Pubitemid 34967427)
86. J.M. Fakruddin, and J. Laurence Interactions among human immunodeficiency virus (HIV)-1, interferon-gamma and receptor of activated NF-kappa B ligand (RANKL): implications for HIV pathogenesis Clinical and Experimental Immunology 137 3 2004 538 545 (Pubitemid 39128080)
87. M.W. Wang, S. Wei, and R. Faccio The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling Journal of Clinical Investigation 114 2 2004 206 213 (Pubitemid 39071625)
88. G. Pan, M. Kilby, and J.M. McDonald Modulation of osteoclastogenesis induced by nucleoside reverse transcriptase inhibitors AIDS Research and Human Retroviruses 22 11 2006 1131 1141 (Pubitemid 44904264)
89. M. Konishi, K. Takahashi, and E. Yoshimoto Association between osteopenia/osteoporosis and the serum RANKL in HIV-infected patients AIDS 19 11 2005 1240 1241 (Pubitemid 41059272)
90. A.P. Malizia, E. Cotter, and N. Chew HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts AIDS Research and Human Retroviruses 23 2 2007 243 250 (Pubitemid 46418337)
91. N.S. Chew, P.P. Doran, and W.G. Powderly Osteopenia and osteoporosis in HIV: pathogenesis and treatment Current Opinion in HIV and AIDS 2 4 2007 318 323 (Pubitemid 46941826)
92. V.A. Triant, T.T. Brown, and H. Lee Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system Journal of Clinical Endocrinology and Metabolism 93 9 2008 3499 3504
93. R. Bedimo, A. Westfall, and H. Drechscler HCV co-infection is associated with a high risk of osteoporotic fractures among HIV-infected patients 18th IAC, Vienna, July 18-23, 2010
94. J.D. Lundgren, M. Battegay, and G. Behrens European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV HIV Medicine 9 2 2008 72 81 (Pubitemid 351232645)
95. L.A. Fitzpatrick Secondary causes of osteoporosis Mayo Clinic Proceedings 77 5 2002 453 468 (Pubitemid 34465153)
96. G. Guaraldi, G. Orlando, and G. Madeddu Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis HIV Clinical Trials 5 5 2004 269 277 (Pubitemid 39545399)
97. K. Mondy, W.G. Powderly, and S.A. Claxton Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection Journal of Acquired Immune Deficiency Syndromes 38 4 2005 426 431 (Pubitemid 40381552)
98. G.A. McComsey, M.A. Kendall, and P. Tebas Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV AIDS 21 2007 2473 2482 (Pubitemid 350145179)
99. M.J. Bolland, A.B. Grey, and A.M. Horne Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial Journal of Clinical Endocrinology and Metabolism 92 4 2007 1283 1288 (Pubitemid 46556399)
100. M. Rodriguez, B. Daniels, and S. Gunawardene High frequency of vitamin D deficiency in ambulatory HIV-Positive patients AIDS Research and Human Retroviruses 25 1 2009 9 14
101. M.M. Rosenvinge, K. Gedela, and A.J. Copas Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency Journal of Acquired Immune Deficiency Syndromes 54 5 2010 496 499
102. C.J. Van Den Bout-Van Den Beukel, L. Fievez, and M. Michels Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy AIDS Research and Human Retroviruses 24 11 2008 1375 1382
103. T. Welz, K. Childs, and F. Ibrahim Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase AIDS 24 12 2010 1923 1928
104. N.J. Mueller, C.A. Fux, and B. Ledergerber High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients AIDS 24 8 2010 1127 1134
105. M. Cozzolino, M. Vidal, and M.V. Arcidiacono HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D AIDS 17 4 2003 513 520 (Pubitemid 36293104)
106. M. Ellfolk, M. Norlin, and K. Gyllensten Regulation of human vitamin D(3) 25-hydroxylases in dermal fibroblasts and prostate cancer LNCaP cells Molecular Pharmacology 75 6 2009 1392 1399
107. C. Stephan Experience with tenofovir disoproxil fumarate for antiretroviral therapy Expert Opinion on Pharmacotherapy 9 7 2008 1197 1209 (Pubitemid 351721756)
108. S. Coca, and M.A. Perazella Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity The American Journal of the Medical Sciences 324 6 2002 342 344 (Pubitemid 36109329)
109. M.A. Perazella Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity The American Journal of the Medical Sciences 325 6 2003 349 362 (Pubitemid 36712657)
110. D. Verhelst, M. Monge, and J.L. Meynard Fanconi syndrome and renal failure induced by tenofovir: a first case report American Journal of Kidney Diseases 40 6 2002 1331 1333 (Pubitemid 35403147)
111. C. Creput, G. Gonzalez-Canali, and G. Hill Renal lesions in HIV-1-positive patient treated with tenofovir AIDS 17 6 2003 935 937 (Pubitemid 36547673)
112. A. Karras, M. Lafaurie, and A. Furco Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus Clinical Infectious Diseases 36 8 2003 1070 1073 (Pubitemid 36513295)
113. K.K. Van Rompay, L.L. Brignolo, and D.J. Meyer Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques Antimicrobial Agents and Chemotherapy 48 5 2004 1469 1487 (Pubitemid 38544348)
114. J.E. Gallant, S. Staszewski, and A.L. Pozniak Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial JAMA 292 2 2004 191 201 (Pubitemid 38917996)
115. F.A. Post, G.J. Moyle, and H.J. Stellbrink Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study Journal of Acquired Immune Deficiency Syndrome 55 1 2010 49 57
116. R.D. Cooper, N. Wiebe, and N. Smith Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients Clinical Infectious Diseases 51 5 2010 496 505
117. A. Mocroft, O. Kirk, and P. Reiss Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients AIDS 24 11 2010 1667 1678
118. G. McComsey, D. Kitch, and E. Daar Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: a prospective, randomized, partially blinded phase III trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV-1 infectio 17th Conference on Retroviruses and Opportunistic infections 2010
119. D.A. Cooper, M. Bloch, and A. Humphries Simplification with fixed-dose tenofovir/emtricitabine or abacavir/lamivudine in adults with suppressed HIV replication; the STEAL study, a randomised, open-label 96 week non-inferiority trial 16th Conference on retroviruses and opportunistic infections 2009
120. K.E. Childs, S.L. Fishman, and C. Constable Short communication: inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users AIDS Research and Human Retroviruses 26 8 2010 855 859
121. I.F. Grigsby, L. Pham, and L.M. Mansky Tenofovir-associated bone density loss Therapeutics and Clinical Risk Management 6 4 2010 1 47